drugset / Trial / NCT04869488
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Main research purpose: To evaluate the effectiveness of Fluzoparib combined with apatinib mesylate in the treatment of patients with metastatic castration-resistant prostate cancer.
Timeline
- Start
- 2021-07-19
- Primary completion
- 2023-02-14
- Completion
- 2023-02-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Abiraterone acetate | Small molecule | — | Oral |
| Comparator | Enzalutamide | Other / unclassified | — | Oral |
| Subject | Fluzoparib | Small molecule | — | Oral |
| Subject | Rivoceranib | Small molecule | — | Oral |
| Comparator | Prednisone | Other / unclassified | — | Oral |